GlassScriptPhysician profile
Holly Suzanne Bordon
NPI 1366647612
$1,609.34
in general payments reported to CMS, 2019-2025
23 companies · $285 in 2025
The $285 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $91.29 · 2021: $180 · 2022: $374 · 2023: $224 · 2024: $313 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $352.79 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $283.85 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $178.00 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.07 | 2020-2022 | |
| Genentech USA, INC. | $135.49 | 2019-2022 | |
| Kaleo, INC. | $77.22 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $54.77 | 2022-2024 | Crysvita |
| Verrica Pharmaceuticals INC. | $49.37 | 2024-2025 | Ycanth |
| Pfizer INC. | $46.28 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $40.29 | 2023-2024 | Flumist Quadrivalent |
| Tris Pharma INC | $37.38 | 2019-2020 | |
| Sobi, INC | $36.29 | 2019-2023 | |
| Cranial Technologies, INC | $30.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $15.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.86 | 2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $15.77 | 2024 | Voxzogo 1.2mg |
| Qiagen, LLC | $15.73 | 2022 | |
| Aytu Biopharma, INC. | $14.12 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.00 | 2020 | |
| Galderma Laboratories, L.P. | $12.85 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.78 | 2019 | |
| Glaxosmithkline, LLC. | $12.48 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Bordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.